

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 604-707	SERIAL NO. 10/763,393			
(Use several sheets if necessary)		APPLICANT VEECH, Richard L.	GROUP			
		FILING DATE JUN 16 2010				
		PATENT & TRADEMARK OFFICE				
		U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Babayan, V. K.; "Medium Chain Triglycerides and Structured Lipids"; *LIPIDS*; Vol. 22, No. 6; pp. 417-420 (1987).

Bach, A.C., et al; "Medium-chain triglycerides: an update"; *The American Journal of Clinical Nutrition* 36; pp. 950-962 (1982).

Declaration of Richard L. Veech, M.D., D. Phil.; European Patent Application No. 04754584.3; For Nutritional Supplements and Therapeutic Compositions Comprising (R)-3-Hydroxybutyrate Derivatives (2 pgs).

DeMichele, S.J., et al; "Enteral nutrition with structured lipid: effect on protein metabolism in thermal injury¹³ⁿ"; *Am. J. Clin. Nutr.*; Vol. 50; pp. 1295-1302 (1989).

Gottenbos, J.J., et al; "The Fatty Acid Composition of Thoracic Lymph Fat of Rats Fed Single Triglycerides"; *Unilever Research Laboratory, Vlaardingen (The Netherlands)*; pp. 272-279.

Hubbard, V.S., et al; "Absorption of Safflower Oil and Structured Lipid Preparations in Patients with cystic Fibrosis"; *LIPIDS*; Vol. 22, No. 6; pp. 424-428 (1987).

Huttenlocher, P.R.; "Ketonemia and Seizures: Metabolic and Anticonvulsant Effects of Two Ketogenic Diets in Childhood Epilepsy"; *Pediat. Res.*, Vol. 10; pp. 536-540 (1976).

Huttenlocher, P.R., et al; "Medium-chain triglycerides as a therapy for intractable childhood epilepsy"; *Neurology*; Vol. 21; pp. 1097-1103 (1971).

Ikeda, I., et al; "Lymphatic Absorption of Structured Glycerolipids Containing Medium-Chain Fatty Acids and Linoleic Acid, and Their Effect on Cholesterol Absorption in Rats"; *LIPIDS*; Vol. 26, No. 5; pp. 369-373 (1991).

Jensen, G.L., et al; "Lymphatic absorption of enteraly fed structured triacylglycerol vs physical mix in a canine model"; *Am. J. Clin. Nutr.*; Vol. 60; pp. 518-524 (1994).

Katz, D.P., et al; "Biochemical and Cellular Basis for Potential Therapeutic Value of n-3 Fatty Acids Derived from Fish Oil"; *Nutrition*; Vol. 9, No. 2; pp. 113-118 (1993).

Das, U.N., et al; "Can essential fatty acids reduce the burden of disease(s)?; *Lipids in Health and Disease*; Vol. 7, No. 9; pp. 1-5 (1008).

Mascioli, E.A., et al; "Novel Triglycerides for Special Medical Purposes"; *Journal of Parenteral and Enteral Nutrition*; Vol. 12, No. 6, Supplement; pp. 127S-132S (1988).

McKenna, M.C., et al; "Linoleic Acid Absorption from Lipid Supplements in Patients with Cystic Fibrosis with Pancreatic Insufficiency and in Control Subjects"; *Journal of Pediatric Gastroenterology and Nutrition*; Vol. 4; pp. 45-51 (1985).

Mok, K.T., et al; "Structured Medium-Chain and Long-Chain Triglyceride Emulsions are Superior to Physical Mixtures in Sparing Body Protein in the Burned Rat"; *Metabolism*; Vol. 33, No. 10; pp. 910-915 (1984).

Communication of a notice of opposition; European Patent Office; European Application No. 01930965.7; dated 18-12-2009; Applicant – Accrea, Inc. (21 pgs).

Ruggiero, V., et al; "LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives"; *Mediators of Inflammation*; Vol. 2; pp. S43-S50 (1993).

Pi-Sunyer, F.X., et al; "Insulin and Ketone Responses to Ingestion of Medium and Long-chain Triglycerides in Man"; *Diabetes*, Vol. 18, No. 2; pp. 96-100 (1969).

*Examiner		Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Initial a copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

A circular stamp with the text "OPAP" at the top, "JUN 16 2010" in the center, and "PATENT & TRADEMARK OFFICE" around the bottom.

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.	JUN 16 2010	SERIAL NO.
604-707	PATENT & TRADEMARK OFFICE	
APPLICANT	10/763,393	

(Use several sheets if necessary)

VEECH, Richard L.

FILING DATE

January 26, 2004

SERIAL NO.

10/763,393

[View all posts by admin](#)

TCIA.U

1614

S-Glycoside Structures

	Small, D.M.; "The Effects of Glyceride Structure on Absorption and Metabolism"; <i>Ann. Rev. Nutr.</i> ; Vol. 11; pp. 413-434 (1991).
	Sobrado, J., et al; "Lipid emulsions and reticuloendothelial system function in healthy and burned guinea pigs"; <i>The American Journal of Clinical Nutrition</i> ; Vol. 42; pp. 855-863 (1985).
	Swift, L.L., et al; "Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans"; <i>Am. J. Clin. Nutr.</i> ; Vol. 52; pp. 834-836 (1990).
	Teo, T.C., et al; "Administration of Structured Lipid Composed of MCT and Fish Oil Reduces Net Protein Catabolism in Enterally Fed Burned Rats"; <i>Ann. Surg.</i> ; Vol. 210, No. 1; pp. 100-107 (1989).
	Yang, L.Y., et al; "Absorption of Short Chain Triacylglycerols from Butter and Coconut"; <i>INFORM</i> ; Vol. 3, No. 4; 1114 (1992).
	Yeh, Y.Y., et al; "Relative Utilization of Fatty Acids for Synthesis of Ketone Bodies and Complex Lipids in the Liver of Developing Rats"; <i>LIPIDS</i> ; Vol. 12, No. 4; pp. 367-374 (1976).
	Web Page Accera; "Uniquely targeting metabolic defects in neurodegenerative disorders; Energy Metabolism"; <i>Accrexa A New Energy in Neuroscience</i> (2 pgs).
	Web Page Accera; "Business Development" (1 pg).
	Reger, M.A., et al; "Effects of β -hydroxybutyrate on cognition in memory-impaired adults"; <i>Neurobiology of Aging</i> ; Vol. 25; pp. 311-314 (2004).
	Henderson, S.T.; "Ketone Bodies as a Therapeutic for Alzheimer's Disease"; <i>Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics</i> ; Vol. 5, pp. 470-480 (2008).

***Examiners**

/Timothy Thomas/

Data Considered

08/18/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 509; Draw line through citation if not in conformance and not considered. **Include**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED OUT
Form PTO-5B-4820 (Also PTO/SB/63A)